TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study

被引：0
|
作者：
Angevin, E.
Lopez, J. A.
Pande, A.
Moldovan, C.
Shi, M.
Soria, J. C.
Wang, X.
Harzstark, A.
Saro, J.
Escudier, B.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Hosp 12 Octubre, E-28041 Madrid, Spain
[3] Novartis Oncol, E Hanover, NJ USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3563
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma
    Kim, K. B.
    Saro, J.
    Moschos, S. S.
    Hwu, P.
    Tarhini, A. A.
    Hwu, W.
    Jones, G.
    Wang, Y.
    Rupani, H.
    Kirkwood, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
    Escudier, Bernard
    Gruenwald, Viktor
    Ravaud, Alain
    Ou, Yen-Chuan
    Castellano, Daniel
    Lin, Chia-Chi
    Gschwend, Juergen E.
    Harzstark, Andrea
    Beall, Sarah
    Pirotta, Nicoletta
    Squires, Matthew
    Shi, Michael
    Angevin, Eric
    CLINICAL CANCER RESEARCH, 2014, 20 (11) : 3012 - 3022
  • [3] Phase II study of dovitinib (TKI258) in patients with progressive metastatic adenoid cystic carcinoma
    Dillon, Patrick Michael
    Moskaluk, Chris
    Fracasso, Paula M.
    Petroni, Gina R.
    Thomas, Christopher Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)
    Angevin, E.
    Gruenwald, V.
    Ravaud, A.
    Castellano, D. E.
    Lin, C. C.
    Gschwend, J. E.
    Harzstark, A. L.
    Chang, J.
    Wang, Y.
    Shi, M. M.
    Escudier, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A PHASE I/II STUDY OF TKI258 (DOVITINIB), A FGFR AND VEGFR INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC RENAL CELL CANCER (MRCC): PRELIMINARY PHASE II RESULTS
    Angevin, E.
    Gruenwald, V.
    Lin, C.
    Ravaud, A.
    Lopez, J. A.
    Kruit, W.
    Tykodi, S.
    Gschwend, J.
    Harzstark, A.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 166 - 166
  • [6] Pharmacokinetic analysis of Asian patients in a phase 2 study of dovitinib (TKI258) in metastatic renal cell carcinoma
    Lin, C. C.
    Ou, Y. C.
    Chang, Y. H.
    Angevin, E.
    Gruenwald, V.
    Chang, J.
    Tan, E.
    Pirotta, N.
    Shi, M.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S191 - S191
  • [7] Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
    Angevin, Eric
    Lopez-Martin, Jose A.
    Lin, Chia-Chi
    Gschwend, Juergen E.
    Harzstark, Andrea
    Castellano, Daniel
    Soria, Jean-Charles
    Sen, Paramita
    Chang, Julie
    Shi, Michael
    Kay, Andrea
    Escudier, Bernard
    CLINICAL CANCER RESEARCH, 2013, 19 (05) : 1257 - 1268
  • [8] GOLD study: An international Phase III study of TKI258/Dovitinib versus Sorafenib in patients with metastatic renal cell cancer (mRCC) as third line therapy
    Gruenwald, V
    Kube, U.
    Eichelberg, C.
    Zuern, C.
    Gschwend, J.
    ONKOLOGIE, 2012, 35 : 202 - 203
  • [9] A phase I study of dovitinib (TKI258) in Japanese patients with advanced solid tumors
    Takiuchi, Hiroya
    Gotoh, Masahiro
    Yoshida, Motoki
    Kii, Takayuki
    Yamashita, Keishi
    Sunakawa, Yu
    Kaneta, Toshikado
    Robson, Matthew
    Kakizume, Tomoyuki
    Sasaki, Yasutsuna
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic rental cell cancer: Phase I results.
    Angevin, E.
    Lin, C.
    Pande, A. U.
    Lopez, J. A.
    Gschwend, J.
    Harzstark, A. L.
    Shi, M.
    Anak, O.
    Escudier, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345